A Novel hERG 1a/1b Stable Cell Line for Drug Screening and Research Applications

New therapies for a wide range of diseases are counter-screened against hERG potassium channels to reduce the risk of acquired long QT syndrome and life-threatening arrhythmias. Despite evidence that cardiac IKr is produced by heteromeric hERG 1a/1b channels (Jones et al., 2004, Sale et al., 2008, Jones et al., 2014), rather than the homomeric hERG 1a typically utilized in screening, implementation of the more native-like channel has been...